EGR1 and pachyonychia congenita: Although the role of the MAP kinase pathway in normal PC biology is not defined, components of the pathway are recurrent targets of mutation in PC neoplasia including both upstream regulators such as the RAS oncogenes and downstream effector EGR1 (23–25).